Genmab Stock Nasdaq Copenhagen
Stocks
DK0010272202
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 115B 17.76B 15.42B 14.38B 13.21B 24.99B 1,690B 25.26B 170B 66.28B 845B 66.71B 65.25B 2,799B | P/E 2026 * |
24.5x | P/E 2027 * | 17x |
|---|---|---|---|---|---|
| Enterprise Value | 135B 20.75B 18.02B 16.8B 15.43B 29.19B 1,974B 29.51B 198B 77.44B 987B 77.94B 76.23B 3,270B | EV / Sales 2026 * |
4.77x | EV / Sales 2027 * | 3.83x |
| Free-Float |
95.41% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Genmab
| 1 day | -0.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2010-05-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 2020-02-29 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 2024-08-15 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 2003-10-31 | |
| Director/Board Member | 58 | 2014-12-31 | |
| Director/Board Member | 75 | 2014-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.33% | +4.14% | - | - | 17.44B | |
| +10.00% | +14.90% | +53.89% | +87.07% | 56.7B | |
| +0.80% | -5.70% | +23.89% | +62.65% | 51.97B | |
| -0.98% | -1.19% | -16.98% | -14.21% | 23.33B | |
| +0.30% | -5.17% | -11.23% | +349.07% | 21.34B | |
| +4.29% | +8.97% | +200.03% | +341.85% | 14.77B | |
| +2.45% | -2.37% | +12.19% | +604.06% | 14.53B | |
| +1.71% | -0.90% | +52.13% | +176.27% | 13.84B | |
| +4.16% | +4.44% | +444.12% | +183.06% | 12.12B | |
| +5.30% | -5.80% | +62.62% | +160.98% | 11.14B | |
| Average | +2.61% | -0.44% | +91.19% | +216.76% | 24.41B | |
| Weighted average by Cap. | +3.35% | +0.97% | +61.86% | +161.96% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 28.25B 4.35B 3.78B 3.52B 3.24B 6.12B 414B 6.19B 41.54B 16.24B 207B 16.34B 15.99B 686B | 33.18B 5.11B 4.44B 4.14B 3.8B 7.19B 486B 7.27B 48.79B 19.07B 243B 19.2B 18.78B 805B |
| Net income | 4.82B 742M 644M 601M 552M 1.04B 70.57B 1.05B 7.08B 2.77B 35.28B 2.79B 2.72B 117B | 7.05B 1.09B 944M 880M 808M 1.53B 103B 1.55B 10.37B 4.06B 51.68B 4.08B 3.99B 171B |
| Net Debt | 19.4B 2.99B 2.6B 2.42B 2.22B 4.2B 284B 4.25B 28.53B 11.15B 142B 11.23B 10.98B 471B | 11.82B 1.82B 1.58B 1.47B 1.35B 2.56B 173B 2.59B 17.38B 6.79B 86.59B 6.84B 6.69B 287B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
